Brief: Cassava Sciences Q3 Basic EPS USD -0.22
12/11/2025 13:00
Nov 12 (Reuters) - Cassava Sciences Q3 operating expenses USD 11.86 million. Q3 net income USD -10.807 million Q3 EPS USD -0.22 Q3 operating income USD -11.86 million
Recent news on Filana Therapeutics
See all newsCassava Sciences says US DOJ has closed investigation into company (updated)
Cassava Sciences rises after US DOJ closes probe into company
Cassava Sciences says US DOJ has closed investigation into company
Brief: Cassava Announces Agreement To Settle Securities Class Action Litigation
Brief: Cassava Sciences Inc - On Dec 15, FDA Places Full Clinical Hold On Cassava's Trial - SEC Filing